That's because the company and Biogen have already concluded that they ... of this trial was known as "change from baseline in the Symbol Digit Modalities Test [SDMT]. This particular test looks ...

The symbol of Biogen Pharmachem Industries ... Niraj Vaghela is chairman and Khushboo Khandelwal is the company secretary for Biogen Pharmachem Industries Ltd. Zero income tax: Investment in ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

Biogen Inc. closed 41.43% below its 52-week high of $238.00, which the company achieved on July 12th.

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Biogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.

Looking at the universe of stocks we cover at Dividend Channel, on 2/11/25, Baker Hughes Company (Symbol: BKR) will trade ex-dividend, for its quarterly dividend of $0.23, payable on 2/21/25.